Trials / Completed
CompletedNCT05826574
A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants
A Phase 1, Open Label, Fixed Sequence Study to Assess the Pharmacokinetics of Brensocatib When Administered Alone and With Multiple Doses of Rifampin (CYP3A Inducer) or Esomeprazole (Proton Pump Inhibitor) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to assess the effects of rifampin on the PK of brensocatib in Part 1 of the study and to assess the effects of esomeprazole on the PK of brensocatib in Part 2 of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brensocatib | Oral tablets. |
| DRUG | Rifampin | Oral capsules. |
| DRUG | Esomeprazole | Oral capsules. |
Timeline
- Start date
- 2023-05-10
- Primary completion
- 2023-07-16
- Completion
- 2023-07-16
- First posted
- 2023-04-24
- Last updated
- 2023-08-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05826574. Inclusion in this directory is not an endorsement.